N4 Pharma: Turner Pope
N4 Pharma and Silicon Valley-based SRI International (‘SRI’) have entered a research collaboration agreement (‘the Agreement’) designed to progress development of preclinical products capable of overcoming barriers that prevent intracellular delivery of large molecule biotherapeutics. SRI is a high reputation not-for-profit scientific research institute, that was originally founded by the trustees of Stanford University in 1946 and today comprises c.1500 professional staff. Its Biosciences division has supported the advancement of >200 drugs to clinical trials. Providing significant validation for Nuvec®, N4P’s unique novel silica nanoparticle delivery technology, the Agreement will utilise SRI’s proprietary FOX Three Molecular Guidance system™ (‘MGS’) platform with a view to advancing development of N4P’s nucleic acid-based therapies. Should combination of the two technologies in due course open new commercial potential, N4P and SRI will work together to identify, develop and pursue related business opportunities.
Read or download the full report here....
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.